Journal article
Ceritinib in ALK-rearranged non-small-cell lung cancer
AT Shaw, DW Kim, R Mehra, DSW Tan, E Felip, LQM Chow, DR Camidge, J Vansteenkiste, S Sharma, T De Pas, GJ Riely, BJ Solomon, J Wolf, M Thomas, M Schuler, G Liu, A Santoro, YY Lau, M Goldwasser, AL Boral Show all
New England Journal of Medicine | MASSACHUSETTS MEDICAL SOC | Published : 2014
Abstract
BACKGROUND: Non-small-cell lung cancer (NSCLC) harboring the anaplastic lymphoma kinase gene (ALK) rearrangement is sensitive to the ALK inhibitor crizotinib, but resistance invariably develops. Ceritinib (LDK378) is a new ALK inhibitor that has shown greater antitumor potency than crizotinib in preclinical studies. METHODS: In this phase 1 study, we administered oral ceritinib in doses of 50 to 750 mg once daily to patients with advanced cancers harboring genetic alterations in ALK. In an expansion phase of the study, patients received the maximum tolerated dose. Patients were assessed to determine the safety, pharmacokinetic properties, and antitumor activity of ceritinib. Tumor biopsies w..
View full abstractGrants
Awarded by European Commission
Funding Acknowledgements
Supported by Novartis Pharmaceuticals, by a grant from the National Cancer Institute (5R01CA164273, to Drs. Shaw and Engelman), by a V Foundation Translational Research Grant (to Drs. Shaw and Engelman), by Be a Piece of the Solution, and by the Evan Spirito Memorial Foundation.